Widetrial, an integrated service and technology platform, is coming on board to support an expanded access program (EAP) that will provide the investigational therapy MN-166 (ibudilast) to amyotrophic lateral sclerosis (ALS) patients who aren’t eligible for clinical trials. The program is funded under a $22 million federal…
Answer ALS and Cedars-Sinai have made openly available their amyotrophic lateral sclerosis (ALS) patient-based stem cell and biodata repository to researchers worldwide. The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized nerve cells called induced pluripotent…
A Phase 2a clinical trial testing Rho kinase (ROCK) inhibitor Bravyl (oral fasudil) in people with amyotrophic lateral sclerosis (ALS) has completed patient enrollment for its high-dose group, the company said. While the REAL trial (NTC05218668) was initially slated to only test a 180 mg daily dose of…
A new biopharmaceutical company has launched in the U.S. with more than $100 million in financing and a goal to develop a genomic medicine targeting the UNC13A protein as a novel treatment for people with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Trace Neuroscience kicked off its…
Alterations in the activity of ancient viral DNA that have been incorporated into the human genome may contribute to the development of amyotrophic lateral sclerosis (ALS), according to a study led by researchers at King’s College London. While earlier studies had started to identify connections between these ancient viruses…
Blood levels of eight small molecules called microRNAs can accurately distinguish people with amyotrophic lateral sclerosis (ALS) from healthy people or those with other neurodegenerative diseases, a study shows. Its developers believe this so-called “ALS fingerprint,” which has now been validated in multiple groups of people and in different…
A man with amyotrophic lateral sclerosis (ALS) recently became the first person to control an Amazon Alexa device with his thoughts, via an investigational, implanted brain-computer interface (BCI) from Synchron. The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper…
A home-based multidisciplinary care model for people living with amyotrophic lateral sclerosis (ALS) was found feasible, and was rated as highly satisfactory by both patients and caregivers, according to a pilot study conducted in Germany. The care model also helped patients avoid hospitalizations and remain at home during the…
A gene therapy aimed at stabilizing connections between motor nerve cells and interneurons — a type of cell that regulates motor nerve cell activity — eased motor dysfunction and promoted motor nerve cell survival in a mouse model of amyotrophic lateral sclerosis (ALS), according to a study by European…
Both beneficial and neurotoxic forms of the mineral selenium were increased in people with SOD1-associated amyotrophic lateral sclerosis (ALS) after six months of treatment with Qalsody (tofersen), a report shows. The elevations, which have been linked to ALS previously, could reflect a change in the antioxidant status of…
Get regular updates to your inbox.